Anti-Human DLL4 & VEGF Bispecific Reference Antibody (Navicixizumab, RUO) (HV571036)

Name: Anti-Human DLL4 & VEGF Bispecific Reference Antibody (Navicixizumab, RUO)
Brand: abinScience
SKU: HV571036
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV571036
Descripción	Navicixizumab (HV571036) is a research-grade recombinant antibody targeting Delta-like protein 4. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG2-kappa
Sistema de expresión	Mammalian cells
Objetivo	Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q9NR61 & P15692
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	Bispecific, OMP-305B83, 1638338-43-8
Fondo	Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG2 Recombinant Isotype Control Antibody (HyHEL-10) (HV988107)

Imágenes

SEC-HPLC

SEC-HPLC detection for Research Grade Navicixizumab.
Bioactivity

Detects DLL4 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Navicixizumab

Referencias

Datasheet

Anti-Human DLL4 & VEGF Bispecific Reference Antibody (Navicixizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Proteínas Recombinantes

Anticuerpos

Kits de Ensayo